Linezolid brain penetration in neurointensive care patients.

Background Linezolid exposure in critically ill patients is associated with high inter-individual variability, potentially resulting in subtherapeutic antibiotic exposure. Linezolid exhibits good penetration into the CSF, but its penetration into cerebral interstitial fluid (ISF) is unknown. Objectives To determine linezolid penetration into CSF and cerebral ISF of neurointensive care patients. Patients and methods Five neurocritical care patients received 600 mg of linezolid IV twice daily for treatment of extracerebral infections. At steady state, blood and CSF samples were collected from arterial and ventricular catheters, and microdialysate was obtained from a cerebral intraparenchymal probe. Results The median f AUC0–24 was 57.6 (24.9–365) mg·h/L in plasma, 64.1 (43.5–306.1) mg·h/L in CSF, and 27.0 (10.7–217.6) mg·h/L in cerebral ISF. The median penetration ratio (f AUCbrain_or_CSF/ f AUCplasma) was 0.5 (0.25–0.81) for cerebral ISF and 0.92 (0.79–1) for CSF. Cerebral ISF concentrations correlated well with plasma (R = 0.93, P < 0.001) and CSF levels (R = 0.93, P < 0.001). The median f AUC0–24/MIC ratio was ≥100 in plasma and CSF for MICs of ≤0.5 mg/L, and in cerebral ISF for MICs of ≤0.25 mg/L. The median fT >MIC was ≥80% of the dosing interval in CSF for MICs of ≤0.5 mg/L, and in plasma and cerebral ISF for MICs of ≤0.25 mg/L. Conclusions Linezolid demonstrates a high degree of cerebral penetration, and brain concentrations correlate well with plasma and CSF levels. However, substantial variability in plasma levels, and thus cerebral concentrations, may result in subtherapeutic tissue concentrations in critically ill patients with standard dosing, necessitating therapeutic drug monitoring. [ABSTRACT FROM AUTHOR]